Company intelligence / Profile preview

GT Sunway Bio

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

GT Sunway Bio is a clinical-stage biotechnology company based in Beijing, China, dedicated to the development of advanced immunotherapies for solid tumors. The company leverages its proprietary CAR-T cell therapy platform to engineer treatments that can effectively penetrate and target malignant cells within complex tumor microenvironments. Its lead program, GT103, targets Glypican-3 (GPC3) and is currently in Phase 1 clinical development for the treatment of advanced hepatocellular carcinoma. Beyond liver cancer, the company is advancing a pipeline of candidates targeting Claudin 18.2 and other validated oncology markers to address unmet needs in gastrointestinal and other solid cancers.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on GT Sunway Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GT Sunway Bio.

Explore the full profile